触媒制药 CPRX 深 沪
等待开盘 09-25 09:30:00 美东时间
19.70
-0.080
-0.40%
华盛通- 最 高19.98
- 今 开19.84
- 成交量 142.71万股
- 最 低 19.50
- 昨 收 19.78
- 总市值 24.03亿
- 52周最高 26.58
- 市盈率 静 15.02
- 换手率 1.17%
- 52周最低 19.15
- 委 比 61.44%
- 总股本 1.22亿
- 历史最高 26.58
- 量 比 0.82
- 振 幅 2.43%
- 历史最低 0.37
- 每 手 1
- 风险率 1.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel
Capricor Therapeutics issued a statement regarding the U.S. FDA's public posting of its Complete Response Letter (CRL) for the Biologics License Application (BLA) for Deramiocel, its investigational cell therapy for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The company was not notified in advance of the posting but acknowledges the FDA's decision. Capricor plans to make its preliminary response to the CRL availabl...
09-09 13:20
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
Catalyst Pharmaceuticals announced that its CEO and management team will participate in four upcoming investor conferences between September 3 and September 9, 2025. The events include the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, H.C. Wainwright Global Investment Conference, and Baird Global Conference. Each session will feature presentations available via webcast links on the company's Investors page, with replays ...
08-28 12:03
Catalyst Pharma Settles Patent Dispute with Lupin
Catalyst Pharma ( ($CPRX) ) has shared an announcement. On August 25, 2025, Cat...
08-26 05:04
Catalyst Pharmaceuticals Reaches Settlement With Lupin To Delay Generic FIRDAPSE Launch Until 2035
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare
08-25 20:06
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
Catalyst Pharmaceuticals and its licensor SERB have settled patent litigation with Lupin Ltd and Lupin Pharmaceuticals, Inc., resolving a dispute over Lupin's application to market a generic version of FIRDAPSE. Under the terms of the settlement, Lupin is prohibited from marketing its generic FIRDAPSE in the U.S. before February 25, 2035, unless specific provisions in the agreement are triggered. The agreement also terminates all ongoing patent l...
08-25 12:03
Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
Capricor Therapeutics has initiated a Phase 1 clinical trial of its StealthX™ exosome-based vaccine, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the U.S. Department of Health and Human Services’ Project NextGen. The trial, which marks a key milestone in vaccine development, aims to evaluate the vaccine's safety and immunogenicity, offering an alternative to mRNA vaccines through a natural delivery system usin...
08-18 13:00
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
<p>Capricor Therapeutics has postponed its Q2 2025 financial results release to August 11, 2025, due to a scheduled FDA meeting about its Deramiocel therapy for DMD-associated cardiomyopathy. A webcast and conference call will review financials and provide updates at 4:30 p.m. ET on August 11.</p>
08-08 12:30
Catalyst Pharma Updates Guidelines for SCLC Treatment
Catalyst Pharma ( ($CPRX) ) just unveiled an announcement. On August 6, 2025, C...
08-08 05:49
Catalyst Pharmaceuticals shares are trading lower. The company reported Q2 financial results.
Catalyst Pharmaceuticals shares are trading lower. The company reported Q2 fina...
08-08 00:31
Milestone Achievement for Hospital Using Catheter Precision’s VIVO System
Heart Hospital of New Mexico has become the first to complete 200 ventricular ablation procedures using Catheter Precision's VIVO system. The VIVO system is a non-invasive 3D imaging tool designed to identify the origin of ventricular arrhythmias pre-procedure, improving workflow and reducing procedure time. Catheter Precision's CEO, David Jenkins, congratulated the hospital for embracing the technology and achieving this milestone. The hospital,...
08-07 12:00
